Market LIVE
Published markets; coverage varies by country
Product profile · United States

QTERN

 ·  Patent Litigation & Settlement History ↓

IngredientDAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE
Application typeNDA
Application209091
Product002
Dosage formTABLET
RouteORAL
Strength5MG;EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Approval date2019-05-02
Marketing statusDISCONTINUED
Status event—
ApplicantASTRAZENECA AB
Product source

Current GenericRadar decision

Year2025
SelectionDISQUALIFIED
ReviewFINAL
Anchor typeFDA_DISCONTINUATION
Anchor date—
Patent anchor2026-04-04
Exclusivity anchor2022-05-02
Protection date2030-06-16
First Final ANDA—
Status event—

FDA_DISCONTINUED; FDA DISC action month 2025-06

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
65151172025-10-04DS/DP/U U-493———
———
65151172026-04-04— ————
—2026-04-04—
65151172026-04-04ORANGE_BOOK U-493YNTRUE_DS
English description not available.
—2026-04-04—
85016982027-06-20DP/U U-493———
———
85016982027-12-20— ————
—2027-12-20—
85016982027-12-20ORANGE_BOOK U-493NNDP
English description not available.
—2027-12-20—
82217862028-03-21DP ————
———
83619722028-03-21U U-493———
———
87162512028-03-21DP ————
———
82217862028-09-21— ————
—2028-09-21—
82217862028-09-21ORANGE_BOOK —NNDP
English description not available.
—2028-09-21—
83619722028-09-21— ————
—2028-09-21—
83619722028-09-21ORANGE_BOOK U-493NNU
English description not available.
—2028-09-21—
87162512028-09-21— ————
—2028-09-21—
87162512028-09-21ORANGE_BOOK —NNDP
English description not available.
—2028-09-21—
79195982029-12-16DS ————
———
79195982030-06-16— ————
—2030-06-16—
79195982030-06-16ORANGE_BOOK —NNDP
English description not available.
—2030-06-16—

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
NS2019-05-022022-05-02English description not available.YY2022-05-02Source

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (8)
TypeDateRoleBasisSource
PATENT2026-04-04HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2027-12-20HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2028-09-21HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2028-09-21HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2028-09-21HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2030-06-16HISTORICAL_CONTEXTEnglish description not available.Source
REGULATORY_EXCLUSIVITY—HISTORICAL_CONTEXTEnglish description not available.Source
REGULATORY_STATUS—TERMINAL_STATUSFDA_DISCONTINUED; FDA DISC action month 2025-06Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.